1. Scrip
  2. >>Business

Vabysmo Is Bright Spot For Roche In Bumpy Q3

Anticipation Grows On Alzheimer’s Result

 
• By Andrew McConaghie

Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.  

Roche_White_Logo
Roche got a big boost from its COVID-19 therapies last year, but does not expect further sales spikes, despite the unpredictability of SARS-CoV2. • Source: Shutterstock

Roche saw its pharma revenues go into reverse as COVID-19 therapies Actemra (tocilizumab) and Ronapreve (casirivimab/imdevimab) fell in the third quarter, but its new eye therapy, Vabysmo (faricimab-svoa), provided the good news with an exceptional lift-off in sales.

Pharma division revenues dropped by 6% to CHF10.84bn ($10.90bn) compared with the same period last year, with the COVID-19 therapies'...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.